nodes	percent_of_prediction	percent_of_DWPC	metapath
Metformin—SLC47A1—Mitoxantrone—lymphatic system cancer	0.34	0.455	CbGbCtD
Metformin—SLC22A2—Cytarabine—lymphatic system cancer	0.153	0.204	CbGbCtD
Metformin—SLC22A1—Cytarabine—lymphatic system cancer	0.133	0.177	CbGbCtD
Metformin—SLC22A3—Vincristine—lymphatic system cancer	0.122	0.164	CbGbCtD
Metformin—NDUFA2—Podofilox—Teniposide—lymphatic system cancer	0.0052	0.398	CbGdCrCtD
Metformin—NDUFA7—Azacitidine—Fludarabine—lymphatic system cancer	0.00155	0.119	CbGdCrCtD
Metformin—NDUFA7—Azacitidine—Cytarabine—lymphatic system cancer	0.00147	0.112	CbGdCrCtD
Metformin—NDUFA2—Azacitidine—Fludarabine—lymphatic system cancer	0.00132	0.101	CbGdCrCtD
Metformin—NDUFA2—Azacitidine—Cytarabine—lymphatic system cancer	0.00125	0.0954	CbGdCrCtD
Metformin—NDUFB3—Azacitidine—Fludarabine—lymphatic system cancer	0.00118	0.09	CbGdCrCtD
Metformin—NDUFB3—Azacitidine—Cytarabine—lymphatic system cancer	0.00111	0.085	CbGdCrCtD
Metformin—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00104	0.00435	CcSEcCtD
Metformin—Infection—Teniposide—lymphatic system cancer	0.00104	0.00432	CcSEcCtD
Metformin—Dehydration—Mitoxantrone—lymphatic system cancer	0.00103	0.0043	CcSEcCtD
Metformin—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00102	0.00426	CcSEcCtD
Metformin—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00101	0.00423	CcSEcCtD
Metformin—Malaise—Fludarabine—lymphatic system cancer	0.00101	0.00422	CcSEcCtD
Metformin—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00101	0.0042	CcSEcCtD
Metformin—Pruritus—Mechlorethamine—lymphatic system cancer	0.001	0.00417	CcSEcCtD
Metformin—Anorexia—Teniposide—lymphatic system cancer	0.000993	0.00415	CcSEcCtD
Metformin—Fungal infection—Methotrexate—lymphatic system cancer	0.000985	0.00411	CcSEcCtD
Metformin—Hypotension—Teniposide—lymphatic system cancer	0.000974	0.00406	CcSEcCtD
Metformin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000967	0.00404	CcSEcCtD
Metformin—Neutropenia—Carmustine—lymphatic system cancer	0.000964	0.00402	CcSEcCtD
Metformin—Myalgia—Fludarabine—lymphatic system cancer	0.000955	0.00399	CcSEcCtD
Metformin—Discomfort—Fludarabine—lymphatic system cancer	0.000944	0.00394	CcSEcCtD
Metformin—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00094	0.00392	CcSEcCtD
Metformin—Sweating increased—Mitoxantrone—lymphatic system cancer	0.000933	0.0039	CcSEcCtD
Metformin—Dyspnoea—Teniposide—lymphatic system cancer	0.000929	0.00388	CcSEcCtD
Metformin—Neutropenia—Vincristine—lymphatic system cancer	0.00092	0.00384	CcSEcCtD
Metformin—Oedema—Fludarabine—lymphatic system cancer	0.000916	0.00382	CcSEcCtD
Metformin—Infection—Fludarabine—lymphatic system cancer	0.00091	0.0038	CcSEcCtD
Metformin—Decreased appetite—Teniposide—lymphatic system cancer	0.000906	0.00378	CcSEcCtD
Metformin—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000901	0.00376	CcSEcCtD
Metformin—Vomiting—Mechlorethamine—lymphatic system cancer	0.000899	0.00375	CcSEcCtD
Metformin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000898	0.00375	CcSEcCtD
Metformin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000897	0.00374	CcSEcCtD
Metformin—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000896	0.00374	CcSEcCtD
Metformin—Rash—Mechlorethamine—lymphatic system cancer	0.000891	0.00372	CcSEcCtD
Metformin—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000891	0.00372	CcSEcCtD
Metformin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00089	0.00372	CcSEcCtD
Metformin—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000885	0.00369	CcSEcCtD
Metformin—Flushing—Bleomycin—lymphatic system cancer	0.000877	0.00366	CcSEcCtD
Metformin—Anorexia—Fludarabine—lymphatic system cancer	0.000873	0.00364	CcSEcCtD
Metformin—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00086	0.00359	CcSEcCtD
Metformin—Feeling abnormal—Teniposide—lymphatic system cancer	0.000859	0.00358	CcSEcCtD
Metformin—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000854	0.00357	CcSEcCtD
Metformin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000852	0.00356	CcSEcCtD
Metformin—Chills—Bleomycin—lymphatic system cancer	0.000848	0.00354	CcSEcCtD
Metformin—Nausea—Mechlorethamine—lymphatic system cancer	0.00084	0.0035	CcSEcCtD
Metformin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000834	0.00348	CcSEcCtD
Metformin—Urticaria—Teniposide—lymphatic system cancer	0.000828	0.00345	CcSEcCtD
Metformin—Abdominal pain—Teniposide—lymphatic system cancer	0.000824	0.00344	CcSEcCtD
Metformin—Erythema—Bleomycin—lymphatic system cancer	0.000823	0.00343	CcSEcCtD
Metformin—Paraesthesia—Fludarabine—lymphatic system cancer	0.000822	0.00343	CcSEcCtD
Metformin—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000821	0.00343	CcSEcCtD
Metformin—Dyspnoea—Fludarabine—lymphatic system cancer	0.000816	0.00341	CcSEcCtD
Metformin—Oedema peripheral—Carmustine—lymphatic system cancer	0.000813	0.00339	CcSEcCtD
Metformin—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000811	0.00338	CcSEcCtD
Metformin—Dyspepsia—Fludarabine—lymphatic system cancer	0.000806	0.00336	CcSEcCtD
Metformin—Decreased appetite—Fludarabine—lymphatic system cancer	0.000796	0.00332	CcSEcCtD
Metformin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000791	0.0033	CcSEcCtD
Metformin—Fatigue—Fludarabine—lymphatic system cancer	0.00079	0.0033	CcSEcCtD
Metformin—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000784	0.00327	CcSEcCtD
Metformin—Constipation—Fludarabine—lymphatic system cancer	0.000783	0.00327	CcSEcCtD
Metformin—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000781	0.00326	CcSEcCtD
Metformin—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000774	0.00323	CcSEcCtD
Metformin—Eye disorder—Carmustine—lymphatic system cancer	0.000771	0.00322	CcSEcCtD
Metformin—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000769	0.00321	CcSEcCtD
Metformin—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000767	0.0032	CcSEcCtD
Metformin—Flushing—Carmustine—lymphatic system cancer	0.000766	0.0032	CcSEcCtD
Metformin—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000763	0.00319	CcSEcCtD
Metformin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000755	0.00315	CcSEcCtD
Metformin—Asthenia—Teniposide—lymphatic system cancer	0.000748	0.00312	CcSEcCtD
Metformin—Malaise—Bleomycin—lymphatic system cancer	0.000742	0.0031	CcSEcCtD
Metformin—Pruritus—Teniposide—lymphatic system cancer	0.000737	0.00308	CcSEcCtD
Metformin—Cardiac disorder—Vincristine—lymphatic system cancer	0.000731	0.00305	CcSEcCtD
Metformin—Malnutrition—Carmustine—lymphatic system cancer	0.000718	0.003	CcSEcCtD
Metformin—Erythema—Carmustine—lymphatic system cancer	0.000718	0.003	CcSEcCtD
Metformin—Angiopathy—Vincristine—lymphatic system cancer	0.000715	0.00298	CcSEcCtD
Metformin—Diarrhoea—Teniposide—lymphatic system cancer	0.000713	0.00298	CcSEcCtD
Metformin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00071	0.00296	CcSEcCtD
Metformin—Chest pain—Bleomycin—lymphatic system cancer	0.0007	0.00292	CcSEcCtD
Metformin—Myalgia—Bleomycin—lymphatic system cancer	0.0007	0.00292	CcSEcCtD
Metformin—Discomfort—Bleomycin—lymphatic system cancer	0.000692	0.00289	CcSEcCtD
Metformin—Chills—Mitoxantrone—lymphatic system cancer	0.000688	0.00287	CcSEcCtD
Metformin—Vision blurred—Carmustine—lymphatic system cancer	0.000677	0.00282	CcSEcCtD
Metformin—Tremor—Carmustine—lymphatic system cancer	0.000673	0.00281	CcSEcCtD
Metformin—Oedema—Bleomycin—lymphatic system cancer	0.000671	0.0028	CcSEcCtD
Metformin—Erythema—Mitoxantrone—lymphatic system cancer	0.000668	0.00279	CcSEcCtD
Metformin—Infection—Bleomycin—lymphatic system cancer	0.000667	0.00278	CcSEcCtD
Metformin—Vomiting—Teniposide—lymphatic system cancer	0.000663	0.00276	CcSEcCtD
Metformin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000657	0.00274	CcSEcCtD
Metformin—Asthenia—Fludarabine—lymphatic system cancer	0.000657	0.00274	CcSEcCtD
Metformin—Rash—Teniposide—lymphatic system cancer	0.000657	0.00274	CcSEcCtD
Metformin—Dermatitis—Teniposide—lymphatic system cancer	0.000656	0.00274	CcSEcCtD
Metformin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000654	0.00273	CcSEcCtD
Metformin—Headache—Teniposide—lymphatic system cancer	0.000653	0.00272	CcSEcCtD
Metformin—Pruritus—Fludarabine—lymphatic system cancer	0.000648	0.0027	CcSEcCtD
Metformin—Anorexia—Bleomycin—lymphatic system cancer	0.00064	0.00267	CcSEcCtD
Metformin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000629	0.00263	CcSEcCtD
Metformin—Hypotension—Bleomycin—lymphatic system cancer	0.000627	0.00262	CcSEcCtD
Metformin—Diarrhoea—Fludarabine—lymphatic system cancer	0.000627	0.00262	CcSEcCtD
Metformin—Hypertension—Carmustine—lymphatic system cancer	0.00062	0.00259	CcSEcCtD
Metformin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000619	0.00259	CcSEcCtD
Metformin—Nausea—Teniposide—lymphatic system cancer	0.000619	0.00258	CcSEcCtD
Metformin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000612	0.00255	CcSEcCtD
Metformin—Chest pain—Carmustine—lymphatic system cancer	0.000611	0.00255	CcSEcCtD
Metformin—Myalgia—Carmustine—lymphatic system cancer	0.000611	0.00255	CcSEcCtD
Metformin—Paraesthesia—Bleomycin—lymphatic system cancer	0.000603	0.00252	CcSEcCtD
Metformin—Malaise—Mitoxantrone—lymphatic system cancer	0.000602	0.00251	CcSEcCtD
Metformin—Dyspnoea—Bleomycin—lymphatic system cancer	0.000599	0.0025	CcSEcCtD
Metformin—Hypertension—Vincristine—lymphatic system cancer	0.000592	0.00247	CcSEcCtD
Metformin—Oedema—Carmustine—lymphatic system cancer	0.000586	0.00245	CcSEcCtD
Metformin—Decreased appetite—Bleomycin—lymphatic system cancer	0.000584	0.00244	CcSEcCtD
Metformin—Myalgia—Vincristine—lymphatic system cancer	0.000584	0.00244	CcSEcCtD
Metformin—Infection—Carmustine—lymphatic system cancer	0.000582	0.00243	CcSEcCtD
Metformin—Vomiting—Fludarabine—lymphatic system cancer	0.000582	0.00243	CcSEcCtD
Metformin—Rash—Fludarabine—lymphatic system cancer	0.000577	0.00241	CcSEcCtD
Metformin—Dermatitis—Fludarabine—lymphatic system cancer	0.000577	0.00241	CcSEcCtD
Metformin—Hypertension—Mitoxantrone—lymphatic system cancer	0.000576	0.00241	CcSEcCtD
Metformin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000574	0.00239	CcSEcCtD
Metformin—Headache—Fludarabine—lymphatic system cancer	0.000574	0.00239	CcSEcCtD
Metformin—Myalgia—Mitoxantrone—lymphatic system cancer	0.000568	0.00237	CcSEcCtD
Metformin—Chest pain—Mitoxantrone—lymphatic system cancer	0.000568	0.00237	CcSEcCtD
Metformin—Lethargy—Methotrexate—lymphatic system cancer	0.000564	0.00235	CcSEcCtD
Metformin—Discomfort—Mitoxantrone—lymphatic system cancer	0.000562	0.00234	CcSEcCtD
Metformin—Oedema—Vincristine—lymphatic system cancer	0.00056	0.00234	CcSEcCtD
Metformin—Anorexia—Carmustine—lymphatic system cancer	0.000559	0.00233	CcSEcCtD
Metformin—Infection—Vincristine—lymphatic system cancer	0.000556	0.00232	CcSEcCtD
Metformin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000553	0.00231	CcSEcCtD
Metformin—Nervous system disorder—Vincristine—lymphatic system cancer	0.000549	0.00229	CcSEcCtD
Metformin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000548	0.00229	CcSEcCtD
Metformin—Hypotension—Carmustine—lymphatic system cancer	0.000548	0.00229	CcSEcCtD
Metformin—Oedema—Mitoxantrone—lymphatic system cancer	0.000545	0.00227	CcSEcCtD
Metformin—Nausea—Fludarabine—lymphatic system cancer	0.000544	0.00227	CcSEcCtD
Metformin—Infection—Mitoxantrone—lymphatic system cancer	0.000541	0.00226	CcSEcCtD
Metformin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000541	0.00226	CcSEcCtD
Metformin—Shock—Mitoxantrone—lymphatic system cancer	0.000536	0.00224	CcSEcCtD
Metformin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000534	0.00223	CcSEcCtD
Metformin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000534	0.00223	CcSEcCtD
Metformin—Urticaria—Bleomycin—lymphatic system cancer	0.000533	0.00223	CcSEcCtD
Metformin—Anorexia—Vincristine—lymphatic system cancer	0.000533	0.00223	CcSEcCtD
Metformin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000529	0.00221	CcSEcCtD
Metformin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000527	0.0022	CcSEcCtD
Metformin—Paraesthesia—Carmustine—lymphatic system cancer	0.000526	0.0022	CcSEcCtD
Metformin—Hypotension—Vincristine—lymphatic system cancer	0.000523	0.00218	CcSEcCtD
Metformin—Dyspnoea—Carmustine—lymphatic system cancer	0.000523	0.00218	CcSEcCtD
Metformin—Somnolence—Carmustine—lymphatic system cancer	0.000521	0.00217	CcSEcCtD
Metformin—Anorexia—Mitoxantrone—lymphatic system cancer	0.000519	0.00217	CcSEcCtD
Metformin—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00051	0.00213	CcSEcCtD
Metformin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00051	0.00213	CcSEcCtD
Metformin—Decreased appetite—Carmustine—lymphatic system cancer	0.00051	0.00213	CcSEcCtD
Metformin—Hypotension—Mitoxantrone—lymphatic system cancer	0.000509	0.00212	CcSEcCtD
Metformin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000506	0.00211	CcSEcCtD
Metformin—Paraesthesia—Vincristine—lymphatic system cancer	0.000502	0.0021	CcSEcCtD
Metformin—Constipation—Carmustine—lymphatic system cancer	0.000501	0.00209	CcSEcCtD
Metformin—Breast disorder—Methotrexate—lymphatic system cancer	0.000499	0.00208	CcSEcCtD
Metformin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000496	0.00207	CcSEcCtD
Metformin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000489	0.00204	CcSEcCtD
Metformin—Decreased appetite—Vincristine—lymphatic system cancer	0.000486	0.00203	CcSEcCtD
Metformin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000486	0.00203	CcSEcCtD
Metformin—Somnolence—Mitoxantrone—lymphatic system cancer	0.000484	0.00202	CcSEcCtD
Metformin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000483	0.00202	CcSEcCtD
Metformin—Feeling abnormal—Carmustine—lymphatic system cancer	0.000483	0.00202	CcSEcCtD
Metformin—Fatigue—Vincristine—lymphatic system cancer	0.000482	0.00201	CcSEcCtD
Metformin—Asthenia—Bleomycin—lymphatic system cancer	0.000482	0.00201	CcSEcCtD
Metformin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00048	0.002	CcSEcCtD
Metformin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000479	0.002	CcSEcCtD
Metformin—Constipation—Vincristine—lymphatic system cancer	0.000478	0.002	CcSEcCtD
Metformin—Pruritus—Bleomycin—lymphatic system cancer	0.000475	0.00198	CcSEcCtD
Metformin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000474	0.00198	CcSEcCtD
Metformin—Fatigue—Mitoxantrone—lymphatic system cancer	0.00047	0.00196	CcSEcCtD
Metformin—Pancreatitis—Methotrexate—lymphatic system cancer	0.000468	0.00195	CcSEcCtD
Metformin—Constipation—Mitoxantrone—lymphatic system cancer	0.000466	0.00194	CcSEcCtD
Metformin—Abdominal pain—Carmustine—lymphatic system cancer	0.000463	0.00193	CcSEcCtD
Metformin—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000458	0.00191	CcSEcCtD
Metformin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000458	0.00191	CcSEcCtD
Metformin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000449	0.00187	CcSEcCtD
Metformin—Neutropenia—Methotrexate—lymphatic system cancer	0.000446	0.00186	CcSEcCtD
Metformin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000446	0.00186	CcSEcCtD
Metformin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000444	0.00185	CcSEcCtD
Metformin—Abdominal pain—Vincristine—lymphatic system cancer	0.000442	0.00185	CcSEcCtD
Metformin—Urticaria—Mitoxantrone—lymphatic system cancer	0.000433	0.00181	CcSEcCtD
Metformin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000431	0.0018	CcSEcCtD
Metformin—Vomiting—Bleomycin—lymphatic system cancer	0.000427	0.00178	CcSEcCtD
Metformin—Drowsiness—Methotrexate—lymphatic system cancer	0.000426	0.00178	CcSEcCtD
Metformin—Infestation—Methotrexate—lymphatic system cancer	0.000426	0.00178	CcSEcCtD
Metformin—Infestation NOS—Methotrexate—lymphatic system cancer	0.000426	0.00178	CcSEcCtD
Metformin—Rash—Bleomycin—lymphatic system cancer	0.000423	0.00177	CcSEcCtD
Metformin—Dermatitis—Bleomycin—lymphatic system cancer	0.000423	0.00177	CcSEcCtD
Metformin—Asthenia—Carmustine—lymphatic system cancer	0.000421	0.00176	CcSEcCtD
Metformin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000403	0.00168	CcSEcCtD
Metformin—Asthenia—Vincristine—lymphatic system cancer	0.000401	0.00168	CcSEcCtD
Metformin—Diarrhoea—Carmustine—lymphatic system cancer	0.000401	0.00167	CcSEcCtD
Metformin—Nausea—Bleomycin—lymphatic system cancer	0.000399	0.00166	CcSEcCtD
Metformin—Asthenia—Mitoxantrone—lymphatic system cancer	0.000391	0.00163	CcSEcCtD
Metformin—Dizziness—Carmustine—lymphatic system cancer	0.000388	0.00162	CcSEcCtD
Metformin—Diarrhoea—Vincristine—lymphatic system cancer	0.000383	0.0016	CcSEcCtD
Metformin—Hepatitis—Methotrexate—lymphatic system cancer	0.000382	0.00159	CcSEcCtD
Metformin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000373	0.00156	CcSEcCtD
Metformin—Vomiting—Carmustine—lymphatic system cancer	0.000373	0.00156	CcSEcCtD
Metformin—Dizziness—Vincristine—lymphatic system cancer	0.00037	0.00154	CcSEcCtD
Metformin—Rash—Carmustine—lymphatic system cancer	0.00037	0.00154	CcSEcCtD
Metformin—Dermatitis—Carmustine—lymphatic system cancer	0.000369	0.00154	CcSEcCtD
Metformin—Headache—Carmustine—lymphatic system cancer	0.000367	0.00153	CcSEcCtD
Metformin—Eye disorder—Methotrexate—lymphatic system cancer	0.000357	0.00149	CcSEcCtD
Metformin—Vomiting—Vincristine—lymphatic system cancer	0.000356	0.00148	CcSEcCtD
Metformin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000355	0.00148	CcSEcCtD
Metformin—Rash—Vincristine—lymphatic system cancer	0.000353	0.00147	CcSEcCtD
Metformin—Dermatitis—Vincristine—lymphatic system cancer	0.000352	0.00147	CcSEcCtD
Metformin—Headache—Vincristine—lymphatic system cancer	0.000351	0.00146	CcSEcCtD
Metformin—Nausea—Carmustine—lymphatic system cancer	0.000348	0.00145	CcSEcCtD
Metformin—Angiopathy—Methotrexate—lymphatic system cancer	0.000347	0.00145	CcSEcCtD
Metformin—Vomiting—Mitoxantrone—lymphatic system cancer	0.000346	0.00145	CcSEcCtD
Metformin—Immune system disorder—Methotrexate—lymphatic system cancer	0.000345	0.00144	CcSEcCtD
Metformin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000344	0.00144	CcSEcCtD
Metformin—Rash—Mitoxantrone—lymphatic system cancer	0.000344	0.00143	CcSEcCtD
Metformin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000343	0.00143	CcSEcCtD
Metformin—Chills—Methotrexate—lymphatic system cancer	0.000343	0.00143	CcSEcCtD
Metformin—Headache—Mitoxantrone—lymphatic system cancer	0.000341	0.00142	CcSEcCtD
Metformin—Erythema—Methotrexate—lymphatic system cancer	0.000333	0.00139	CcSEcCtD
Metformin—Malnutrition—Methotrexate—lymphatic system cancer	0.000333	0.00139	CcSEcCtD
Metformin—Nausea—Vincristine—lymphatic system cancer	0.000332	0.00139	CcSEcCtD
Metformin—Dysgeusia—Methotrexate—lymphatic system cancer	0.000326	0.00136	CcSEcCtD
Metformin—Nausea—Mitoxantrone—lymphatic system cancer	0.000324	0.00135	CcSEcCtD
Metformin—Vision blurred—Methotrexate—lymphatic system cancer	0.000313	0.00131	CcSEcCtD
Metformin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000309	0.00129	CcSEcCtD
Metformin—Malaise—Methotrexate—lymphatic system cancer	0.0003	0.00125	CcSEcCtD
Metformin—Chest pain—Methotrexate—lymphatic system cancer	0.000283	0.00118	CcSEcCtD
Metformin—Myalgia—Methotrexate—lymphatic system cancer	0.000283	0.00118	CcSEcCtD
Metformin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000281	0.00117	CcSEcCtD
Metformin—Discomfort—Methotrexate—lymphatic system cancer	0.00028	0.00117	CcSEcCtD
Metformin—Infection—Methotrexate—lymphatic system cancer	0.00027	0.00113	CcSEcCtD
Metformin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000266	0.00111	CcSEcCtD
Metformin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000266	0.00111	CcSEcCtD
Metformin—Skin disorder—Methotrexate—lymphatic system cancer	0.000264	0.0011	CcSEcCtD
Metformin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000262	0.0011	CcSEcCtD
Metformin—Anorexia—Methotrexate—lymphatic system cancer	0.000259	0.00108	CcSEcCtD
Metformin—Hypotension—Methotrexate—lymphatic system cancer	0.000254	0.00106	CcSEcCtD
Metformin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000247	0.00103	CcSEcCtD
Metformin—Paraesthesia—Methotrexate—lymphatic system cancer	0.000244	0.00102	CcSEcCtD
Metformin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000242	0.00101	CcSEcCtD
Metformin—Somnolence—Methotrexate—lymphatic system cancer	0.000241	0.00101	CcSEcCtD
Metformin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000239	0.000997	CcSEcCtD
Metformin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000236	0.000985	CcSEcCtD
Metformin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000234	0.000978	CcSEcCtD
Metformin—Fatigue—Methotrexate—lymphatic system cancer	0.000234	0.000977	CcSEcCtD
Metformin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000224	0.000934	CcSEcCtD
Metformin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000222	0.000926	CcSEcCtD
Metformin—Urticaria—Methotrexate—lymphatic system cancer	0.000216	0.0009	CcSEcCtD
Metformin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000215	0.000896	CcSEcCtD
Metformin—Asthenia—Methotrexate—lymphatic system cancer	0.000195	0.000813	CcSEcCtD
Metformin—Pruritus—Methotrexate—lymphatic system cancer	0.000192	0.000802	CcSEcCtD
Metformin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000186	0.000775	CcSEcCtD
Metformin—Dizziness—Methotrexate—lymphatic system cancer	0.00018	0.000749	CcSEcCtD
Metformin—Vomiting—Methotrexate—lymphatic system cancer	0.000173	0.00072	CcSEcCtD
Metformin—Rash—Methotrexate—lymphatic system cancer	0.000171	0.000714	CcSEcCtD
Metformin—Dermatitis—Methotrexate—lymphatic system cancer	0.000171	0.000714	CcSEcCtD
Metformin—Headache—Methotrexate—lymphatic system cancer	0.00017	0.00071	CcSEcCtD
Metformin—Nausea—Methotrexate—lymphatic system cancer	0.000161	0.000673	CcSEcCtD
